Corcept Therapeutics Incorporated (CORT) financial statements (2022 and earlier)

Company profile

Business Address 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments223,535 275,962206,76088,74451,536
Cash and cash equivalents77,617 31,26941,62531,06251,536
Short-term investments145,918 244,693165,13557,682 
Receivables29,025 19,92817,58815,3009,860
Inventory, net of allowances, customer advances and progress billings4,988 5,4244,7324,5762,329
Inventory4,988 5,4244,7324,5762,329
Other undisclosed current assets8,915 6,0447,74015,5651,964
Total current assets:266,463 307,358236,820124,18565,689
Noncurrent Assets
Inventory, Noncurrent12,962 11,98111,5103,8002,835
Operating lease, right-of-use asset514 3,446
Property, plant and equipment1,002 1,050655518205
Long-term investments and receivables112,277 39,352 15,281 
Long-term investments112,277 39,352 15,281 
Deferred income tax assets27,455 45,677
Other noncurrent assets3,083 3,448505024
Deferred tax assets, net 76,703 
Other undisclosed noncurrent assets   62,659  
Total noncurrent assets:157,293 104,95474,87496,3523,064
TOTAL ASSETS:423,756 412,312311,694220,53768,753
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities34,573 30,80632,05227,32211,243
Accounts payable6,908 7,5378,2668,5792,290
Accrued liabilities27,665 23,26923,78618,7438,953
Debt  1,558  14,664
Other undisclosed current liabilities12,968 6,4773,5212,2471,467
Total current liabilities:47,541 38,84135,57329,56927,374
Noncurrent Liabilities
Long-term debt and lease obligation  1,903   
Operating lease, liability  1,903
Liabilities, other than long-term debt409 386239  
Accounts payable and accrued liabilities409 386239  
Total noncurrent liabilities:409 2,289239  
Total liabilities:47,950 41,13035,81229,56927,374
Stockholders' equity
Stockholders' equity attributable to parent375,806 371,182275,882190,96841,379
Common stock127 120117115113
Treasury stock, value(410,411) (62,704)(23,657)  
Additional paid in capital591,349 457,060417,228384,074363,534
Accumulated other comprehensive income (loss)(227) 261(70)(75) 
Retained earnings (accumulated deficit)194,968 (23,555)(117,736)(193,146)(322,268)
Total stockholders' equity:375,806 371,182275,882190,96841,379
TOTAL LIABILITIES AND EQUITY:423,756 412,312311,694220,53768,753

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues365,978 306,486251,247159,20181,321
Revenue, net159,20181,321
Cost of revenue
(Cost of Goods and Services Sold)
(5,281) (5,504)(5,215)(3,554)(2,058)
Gross profit:360,697 300,982246,032155,64779,263
Operating expenses(236,220) (189,376)(156,536)(102,792)(69,084)
Operating income:124,477 111,60689,49652,85510,179
Interest and debt expense    (14)(2,039)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  5,0702,657(35) 
Income from continuing operations before equity method investments, income taxes:124,477 116,67692,15352,8068,140
Other undisclosed income from continuing operations before income taxes529     
Income from continuing operations before income taxes:125,006 116,67692,15352,8068,140
Income tax expense (benefit)(12,494) (22,495)(16,743)76,316 
Net income available to common stockholders, diluted:112,512 94,18175,410129,1228,140

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income:112,512 94,18175,410129,1228,140
Other comprehensive income (loss)(642) 331   
Comprehensive income:111,870 94,51275,410129,1228,140
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   5(75) 
Comprehensive income, net of tax, attributable to parent:111,870 94,51275,415129,0478,140

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: